TIM-3 inhibits CD8+ T-cell responses in early T-ALL [67], and higher numbers of TIM-3+/PD-1+ CD4+ T cells or TIM-3+ CD4+ T cells predict poor survival in adult B-ALL [15] and pediatric B-ALL [17]. This evidence concerns the gene HAVCR2 and acute lymphoblastic leukemia.